TLDR
- INM jumps 135% on merger with Mentari and $290M private placement.
- Combined company to trade as Mentari Therapeutics on Nasdaq soon.
- MT-001 and MT-002 target migraine with promising clinical data.
- Private placement funds operations through 2028 and key clinical milestones.
- Merger strengthens INM’s market infrastructure and therapeutic pipeline.
InMed Pharmaceuticals, Inc. (INM) closed at $1.60, up 135.05%, before slipping after hours to $1.52. The stock rally followed news of an all-stock merger agreement with Mentari Therapeutics, Inc. The merger combines Mentari’s migraine therapy pipeline with InMed’s public market platform to accelerate new drug development.
InMed Pharmaceuticals Inc., INM
The deal positions the combined company to operate as Mentari Therapeutics under a new Nasdaq ticker symbol. The transaction aligns both entities to target migraine, a neurological disorder affecting over one billion people globally. Investors reacted strongly to the growth potential and market expansion opportunities.
The announcement included a concurrent $290 million private placement to fund operations through 2028. Leading investment firms such as Fairmount, Commodore Capital, and a16z Bio + Health participated. The financing ensures full operational funding beyond anticipated clinical milestones from Mentari’s lead programs.
Pipeline Programs Focus on Migraine Therapies
Mentari’s MT-001 program targets PACAP with Phase 2a proof-of-concept data expected in 2028. MT-002 is a bispecific antibody addressing CGRP and PACAP with Phase 1 data expected in 2027. Both programs aim to provide alternative therapies for chronic and episodic migraine sufferers.
Current treatments do not achieve a 50% reduction in monthly migraine days for 40-50% of patients. Fewer than one-third of patients reach a 75% reduction with existing therapies. The programs are designed to address these unmet clinical needs effectively.
The programs were discovered by Paragon Therapeutics and show comparable or superior in vitro potency. Pharmacokinetic profiles in non-human primates suggest feasible subcutaneous dosing in humans. These results support rapid clinical development and potential best-in-class positioning.
Private Placement Strengthens Financial Position
The private placement attracted multiple top-tier investment management firms. Gross proceeds of approximately $290 million will fully fund development and operational activities. The financing provides stability and resources for the combined company’s strategic roadmap.
Funds are expected to cover key clinical datasets and support the parallel lead programs. Investors anticipate accelerated timelines for regulatory submission and market entry. The combination of capital and market infrastructure enhances competitive positioning in migraine treatment.
The merger aligns with InMed’s strategy to expand its therapeutic and commercial footprint. Integration with Mentari strengthens research capabilities and pipeline diversification. The transaction also opens opportunities for long-term growth and shareholder value creation.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
